Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
 Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016; 893:1-19.
 Fuentes HE, Tafur AJ, Caprini JA. Cancer-associated thrombosis. Dis Mon. 2016 May;62(5):121-58.
 Vedovati MC, Giustozzi M, Becattini C. Venous thromboembolism and cancer: Current and future role of direct acting oral anticoagulants. Thromb Res. 2019 May; 177:33-41.
 Rodrigues CA, Ferrarotto R, Kalil Filho R, et al. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis. 2010 Jul;30(1):67-78.
 Edgington TS, Mackman N, Brand K, et al. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991 Jul 12;66(1):67-79.
 Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2012 Feb;141(2 Suppl):e24S-e43S.
 Bick RL, Ucar K. Hypercoagulability and thrombosis. Hematol Oncol Clin North Am. 1992 Dec;6(6):1421-31.
 Zhou YX, Yang ZM, Feng J, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Tumour Biol. 2013 Dec;34(6):3701-4.
 Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006 Aug;53(2):205-10.
 Ma X, Li Y, Zhang J, et al. Prognostic role of D-dimer in patients with lung cancer: a meta-analysis. Tumour Biol. 2014 Mar;35(3):2103-9.
 Zhang PP, Sun JW, Wang XY, et al. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Eur J Surg Oncol. 2013 Sep;39(9):951-6.
 Jiang HG, Li J, Shi SB, et al. Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer. Med Oncol. 2014 Jul;31(7):22.
 Zhu LR, Li J, Chen P, et al. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clin Transl Oncol. 2016 Feb;18(2):178-88.
 Chen Y, Yu H, Wu C, et al. Prognostic value of plasma D-dimer levels in patients with small-cell lung cancer. Biomed Pharmacother. 2016 Jul;81: 210-217.
 Jiang X, Mei X, Wu H, et al. D-dimer level is related to the prognosis of patients with small cell lung cancer. Ann Transl Med. 2017 Oct;5(20):394.
 Zhang C, Jia Y, Jia Y, et al. Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer. Int J Clin Oncol. 2018 Dec;23(6):1070-1075.
 Chen RZ. Relationship of LDH, α-HBD and D-dimer with survival time of small cell lung cancer patients [D]. Dalian: Dalian Medical University, 2018: 1-45.
 Chen C, Li LY. Prognostic analysis of pretreatment platelet, fibrinogen and D-dimer levels for small cell lung cancer after complete resection. Modern Oncology. 2019,27(07): 1148-1153.
 Fan S, Zhao G, An G. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer. J Int Med Res. 2019 Jan;47(1):215-224.
 Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7;8:16.
 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–60
 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010 Sep;25(9):603-5.
 Taguchi O, Gabazza EC, Yasui H, et al. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997 Jun;52(6):563-5.
 Nagy Z, Horváth O, Kádas J, et al. D-Dimer as a Potential Prognostic Marker. Pathol Oncol Res. 2012 Jul;18(3):669-74.
 Han D, ó Hartaigh B, Lee JH, et al. Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism. PLoS One. 2016 Apr 13;11(4):e0153514.
 Fei X, Wang H, Yuan W, et al. Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. Biomed Res Int. 2017; 2017:8983763.
 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein Thrombosis. Lancet. 2012 May 12;379(9828):1835-46.
 Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005 Sep;12 Suppl 1:5-10.
 Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745–749
 Gieseler F, Lühr I, Kunze T, et al. Activated coagulation factors in human malignant eﬀusions and their contribution to cancer cell metastasis and therapy. Thromb Haemost. 2007; 97:1023–1030
 Gil-Bernabė AM, Ferjančič Š, Tlalka M, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012; 119(13):3164–3175
 Zhang P, Sun J, Lu J, et al. Correlation between baseline plasma D-dimer levels and prognosis in patients with non-small cell lung cancer. Chin J Oncol. 2013; 35(10):747–750
 Gieseler F, Lühr I, Kunze T, et al. Activated coagulation factors in human malignant eﬀusions and their contribution to cancer cell metastasis and therapy. Thromb Haemost. 2007; 97:1023–1030.